Showing results (311-320 of 324) with videos related to

Sort By:
Pageof 33
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 2020
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancersG Saturno, F Lopes, I Niculescu-Duvaz, et al.
Analytical Biochemistry|February 8, 2006
A fluorescence polarization assay for inhibitors of Hsp90R Howes, X Barril, B W Dymock, et al.
Pediatric Blood & Cancer|December 2, 2016
A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemiaB Vormoor, G J Veal, M J Griffin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 2014
Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I databaseP A Cassier, V Polivka, I Judson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2012
Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapyN Penel, G D Demetri, J Y Blay, et al.
Pediatric Blood & Cancer|January 24, 2017
Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study)Brice Fresneau, A Hackshaw, D S Hawkins, et al.
Leukemia|February 23, 2012
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patternsA S Moore, A Faisal, D Gonzalez de Castro, et al.
British Journal of Cancer|May 27, 2010
Guidelines for the welfare and use of animals in cancer researchP Workman, E O Aboagye, F Balkwill, et al.
Blood Cancer Journal|April 1, 2017
Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle controlC Pawlyn, M D Bright, A F Buros, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 25, 2020
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancerM P Kolinsky, P Rescigno, D Bianchini, et al.
Pageof 33